Related Experiment Video
Updated: Nov 7, 2025
06:16
Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
Published on: April 19, 2024
1.3K
Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review
Machteld Sillen1, Paul J Declerck1
1Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, B-3000 Leuven, Belgium.
International Journal of Molecular Sciences
|April 30, 2021
Summary
Thrombin activatable fibrinolysis inhibitor (TAFI) regulates blood clot breakdown. Understanding TAFI
Area of Science:
- Biochemistry
- Hematology
- Molecular Biology
Background:
- Thrombin activatable fibrinolysis inhibitor (TAFI) is a key regulator of the fibrinolytic system.
- TAFI acts as a bridge between coagulation and fibrinolysis.
- Dysregulation of TAFI is implicated in thrombotic diseases.
Purpose of the Study:
- To review the biochemical properties of TAFI.
- To discuss the physiological and pathophysiological roles of TAFI.
- To explore strategies for modulating TAFI activity to stimulate fibrinolysis.
Main Methods:
- Literature review of biochemical and physiological studies on TAFI.
- Analysis of the role of TAFI in coagulation and fibrinolysis.
- Examination of therapeutic strategies targeting TAFI.
Main Results:
- TAFI is a proenzyme activated by thrombin, plasmin, or the thrombin/thrombomodulin complex.
- Activated TAFI potently inhibits fibrinolysis.
- TAFI's involvement in thrombotic disorders necessitates the development of antagonists.
Conclusions:
- TAFI is a critical target for therapeutic intervention in thrombotic conditions.
- Modulating TAFI activity offers a promising approach to enhance fibrinolysis.
- Further research into TAFI antagonism is crucial for developing novel antithrombotic therapies.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
90
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
90
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
01:16Clot Retraction and Fibrinolysis
7.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
816
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
816
01:20Extrinsic and Intrinsic Pathways of Hemostasis
10.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.5K